EuCorVac-19 vaccine gets greenlight for trials
Phase 1 clinical trials will be conducted on healthy adults to test the substance’s safety and the level of antibodies it could create in the human body.
The Eubiologics vaccine candidate, EuCorVac-19, delivers immune boosters in liposomes, which are like nano-sized spheres. It is a recombinant vaccine made with genetic recombination technology. The surface antigen of the vaccine stimulates the immune cell to produce neutralizing antibodies to fight the Covid-19 virus.
As of Wednesday, seven vaccine candidates and 15 coronavirus treatment candidates are undergoing clinical trials in Korea.
BY SONG KYOUNG-SON [firstname.lastname@example.org]